Enhanced anti-tumor activity of the Multi-Leu peptide PACE4 inhibitor transformed into an albumin-bound tumor-targeting prodrug (Q61796165)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30765725 AND SRC:MED&resulttype=core&format=json

23 April 2020

title

Enhanced anti-tumor activity of the Multi-Leu peptide PACE4 inhibitor transformed into an albumin-bound tumor-targeting prodrug (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30765725 AND SRC:MED&resulttype=core&format=json

23 April 2020

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30765725 AND SRC:MED&resulttype=core&format=json

23 April 2020

author name string

Anna Kwiatkowska

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30765725 AND SRC:MED&resulttype=core&format=json

23 April 2020

Frédéric Couture

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30765725 AND SRC:MED&resulttype=core&format=json

23 April 2020

Samia Ait-Mohand

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30765725 AND SRC:MED&resulttype=core&format=json

23 April 2020

Roxane Desjardins

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30765725 AND SRC:MED&resulttype=core&format=json

23 April 2020

Brigitte Guérin

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30765725 AND SRC:MED&resulttype=core&format=json

23 April 2020

Robert Day

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30765725 AND SRC:MED&resulttype=core&format=json

23 April 2020

language of work or name

English

0 references

publication date

14 February 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30765725 AND SRC:MED&resulttype=core&format=json

23 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30765725 AND SRC:MED&resulttype=core&format=json

23 April 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30765725 AND SRC:MED&resulttype=core&format=json

23 April 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30765725 AND SRC:MED&resulttype=core&format=json

23 April 2020

page(s)

2118

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30765725 AND SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

23 April 2020

copyright license

start time

14 February 2019

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Cancer statistics, 2016

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

Proprotein convertase inhibition: Paralyzing the cell's master switches

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

Molecular Validation of PACE4 as a Target in Prostate Cancer

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

Role of proprotein convertases in prostate cancer progression

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

miR-124 exhibits antiproliferative and antiaggressive effects on prostate cancer cells through PACE4 pathway

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

The biology and therapeutic targeting of the proprotein convertases

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

PACE4 Undergoes an Oncogenic Alternative Splicing Switch in Cancer

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

The Multi-Leu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

PACE4 inhibitors and their peptidomimetic analogs block prostate cancer tumor progression through quiescence induction, increased apoptosis and impaired neovascularisation

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

Design, synthesis, and structure-activity relationship studies of a potent PACE4 inhibitor

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

Novel Insights into Structure-Activity Relationships of N-Terminally Modified PACE4 Inhibitors.

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

Strategic approaches to optimizing peptide ADME properties

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

Macrocyclization of a potent PACE4 inhibitor: Benefits and limitations.

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

A portable albumin binder from a DNA-encoded chemical library

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

Half-life extended biotherapeutics

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

Acylated heptapeptide binds albumin with high affinity and application as tag furnishes long-acting peptides

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

A clinical update of using albumin as a drug vehicle - a commentary

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

Optimization of an albumin-binding prodrug of Doxorubicin that is cleaved by prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

Development of a novel albumin-binding prodrug that is cleaved by urokinase-type-plasminogen activator (uPA)

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

Gp60 Activation Mediates Albumin Transcytosis in Endothelial Cells by Tyrosine Kinase-dependent Pathway

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles.

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: An in vitro and in vivo evaluation study

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

In vivo evaluation of a novel albumin-binding prodrug of doxorubicin in an orthotopic mouse model of prostate cancer (LNCaP)

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

Prognostic value of serum markers for prostate cancer

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

Prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

PACE4-based molecular targeting of prostate cancer using an engineered ⁶⁴Cu-radiolabeled peptide inhibitor

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

Contribution of linker stability to the activities of anticancer immunoconjugates

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

Tunable Degradation of Maleimide–Thiol Adducts in Reducing Environments

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

Comparative study of 64Cu/NOTA-[D-Tyr6,βAla11,Thi13,Nle14]BBN(6-14) monomer and dimers for prostate cancer PET imaging

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

Rational Design of a Highly Potent and Selective Peptide Inhibitor of PACE4 by Salt Bridge Interaction with D160 at Position P3.

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

Positional Scanning Identifies the Molecular Determinants of a High Affinity Multi-Leucine Inhibitor for Furin and PACE4.

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

Preparation and characterization of albumin conjugates of a truncated peptide YY analogue for half-life extension

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

Peptide Half-Life Extension: Divalent, Small-Molecule Albumin Interactions Direct the Systemic Properties of Glucagon-Like Peptide 1 (GLP-1) Analogues.

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

Pursuit of a perfect insulin.

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

1 reference

https://api.crossref.org/works/10.1038/S41598-018-37568-6

7 January 2021

Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors

1 reference

12 December 2020

Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen.

1 reference

12 December 2020

Androgen deprivation therapy in the treatment of advanced prostate cancer

1 reference

12 December 2020

Twenty Years of PSA: From Prostate Antigen to Tumor Marker

1 reference

12 December 2020

10.1038/S41598-018-37568-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30765725 AND SRC:MED&resulttype=core&format=json

23 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30765725 AND SRC:MED&resulttype=core&format=json

23 April 2020

PubMed publication ID

30765725

1 reference